News | June 05, 2024
AstraZeneca completes acquisition of Fusion Pharmaceuticals
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
